HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), providing a comprehensive look at what could become the first-ever CAR-T therapy approved for an autoimmune disease.

By FierceBiotech · Apr 23, 2026 · via FierceBiotech
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset

Image: FierceBiotech

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
PipelineFiercePharma ↗
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.…
Apr 23, 2026
Moderna continues bird flu vax study, but limits work in the U.S.
PipelineSTAT News ↗
Moderna continues bird flu vax study, but limits work in the U.S.
Flu shot no longer mandated for U.S. troops, "healthy" snacks, and other news from Morning Rounds…
Apr 22, 2026
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
PipelineFierceBiotech ↗
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, R…
Apr 22, 2026